Dr. John Cush RheumNow
4 years 6 months ago
Increased SLE Flares with HCQ Reduction
Concerns about the long-term safety of HCQ often results in dose reduction or drug discontinuation; yet a study shows that, for those in remission, HCQ taper/discontinuation resulted in a higher rate of SLE flares.
https://t.co/BROdm7zLaw https://t.co/2cEDEc2eOn
Dr. John Cush RheumNow
4 years 6 months ago
OP is worse w/ Inflammation; would biologics reduce OP and Fx risk? Swedish study of 24,678 RA pts, 4265 on biologics - Over time, the OP Fx rates were 12.1 vs 13.0 per 1000PY with and without biologics (HR 0.97; 0.78-1.20); Thus no Fx benefit https://t.co/d2zGd0WWoa https://t.co/Z9HVMUQd5U
Dr. John Cush RheumNow
4 years 6 months ago
2/28, was “Rare Disease Day” in the USA, w/many tributes to the patients, doctors & researchers dedicated to these disorders. Moreover, it was a great opportunity to shout about the many rare conditions that don’t get enough press, praise or funding.
https://t.co/ft8Y8Mmdnz https://t.co/WqhRGzNRtS
Dr. John Cush RheumNow
4 years 6 months ago
NEJM case - Whats the diagnosis? 31yoM w/ 10yr hx of clubbing, arthralgias, nailfold hyperpigmentation, Tender DIPs, toes; xrays showed bony proliferation. Labs and PET were normal. Rx w/ NSAIDs and improved w/ specific Rx? https://t.co/kwkIsOgnW5 https://t.co/NsBqe3rxFP
The ACR has updated its clinical guidelines for the management of juvenile idiopathic arthritis (JIA), with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA (with and without macrophage activation syndrome); only the latter, systemic JIA recommendations are reported herein.
Drug survival may be the best measure of efficacy and safety. A new study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.
Dr. John Cush RheumNow
4 years 6 months ago
Top February Tweet:
Positive Results from the DOA (Duloxetine in OsteoArthritis) Study
https://t.co/Is56PBxpIr https://t.co/xEh6zbx9nr
Dr. John Cush RheumNow
4 years 6 months ago
With H. Zoster on JAK inhib; you can continue JAKi @ low risk. Study of 416 RA pts on JAKi, 8% HZ reactivation (age 60 yrs, 42% Pred) after 11 mos. 72% cont JAKi during HZ, 15% temporarily D/C & resumed. Only 1 pt had HZ re-reactivation https://t.co/dJqhlhGEda
Dr. John Cush RheumNow
4 years 6 months ago
Polarized microscopy of synovial fluid to identify uric acid crystals was shown to high utility and reliability in a study of 5 rheumatologists (4 consultants, 1 registrar). 50 SF samples - good agreement w/ κ = 0.71 for MSU, 0.88 for CPP https://t.co/5c7N7spc0t https://t.co/9wXsHuCY6D
Dr. John Cush RheumNow
4 years 6 months ago
The worldwide Psoriatic arthritis treatment market is expected to grow from $7.89 billion in 2021 to $8.92 billion in 2022 https://t.co/5gdsUgM08y
Dr. John Cush RheumNow
4 years 6 months ago
Pharma payments to rheums. Study of 4822 rheums in Medicare, 77% recv some pharma payment. For every $100 in food/beverage payments, prescribing increased 1.5-14%. For every $1000 in consulting, prescribing increased <5%. https://t.co/tKsRIBbFdt https://t.co/HN2yiTBkPh
Dr. John Cush RheumNow
4 years 6 months ago
Phone Calls about Labs
How to handle "labs" and expectations.
QD Clinic is sponsored by RheumNow Live (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/WzIGihU1UR https://t.co/uvctRtbUEK
Dr. John Cush RheumNow
4 years 6 months ago
INBUILD Study of 170 pts with autoimmune related ILD showed nintedanib signifi. slowed the rate of FVC decline in FVC decline over 52 wks (NIN -75.9 mL/yr vs PBO -178.6 mL/yr). AE's (mostly diarrhea) leading to D/C was NIN 17.1% vs PBO 10.2% https://t.co/VG5oPBU0VC https://t.co/vTkzcwskuJ
